Full Breakdown
Federal Appeals Court Blocks Mail Distribution of Abortion Pill mifepristone
5/2/2026, 11:18:08 AM
Core Ruling Restores In-Person Requirement
On May 1, 2026 a three-judge panel of the New Orleans-based 5th U.S. Circuit Court of Appeals issued a unanimous, temporary nationwide injunction that restores the 2021 rule requiring mifepristone to be prescribed and dispensed only in person, overturning the 2023 FDA policy that allowed telemedicine and mailing. An appeal to the Supreme Court is expected.
Background & Context
The 2022 Supreme Court decision that ended Roe v. Wade let states enforce abortion bans. The FDA lifted the in-person dispensing rule for mifepristone in April 2021 during COVID-19 and made it permanent in 2023. The agency is now conducting a safety review ordered by the Trump administration, slated to finish by October 2026.
Data & Statistics
Approved in 2000, mifepristone with misoprostol accounts for about two-thirds of U.S. abortions. Over 3.7 million women used it from 2000-2018. In 2025, Louisiana recorded 9,350 telehealth abortions, and roughly one-quarter of patients nationwide obtain medication abortions via telemedicine.
Official Statements & Key Actors
Louisiana Attorney General Liz Murrill said the ruling “defends women and babies.” New York Attorney General Letitia James called mifepristone “safe, effective and essential.” Reproductive Freedom for All’s Mini Timmaraju called the case “built on debunked, junk science.” The National Right to Life Committee’s Carol Tobias said the decision “restores a critical layer of oversight.” The FDA declined comment.
Criticism & Opposition
The ACLU’s Julia Kaye warned the order will “affect patients’ access to abortion and miscarriage care in every state.” Reproductive Freedom for All called it a “shameless packaging of lies.” Guttmacher Institute’s Kelly Baden said it would “severely limit access to mifepristone in every state.”
Impact on Access
The in-person rule removes a major channel for patients in both ban states and permissive states. Rural, low-income, disabled, intimate-partner-violence survivors and communities of color face the steepest barriers. Non-abortion uses, such as miscarriage management, are also jeopardized.
Conflicting Reports & Gaps
The court noted the FDA “could not say when its safety review might be complete” and that adverse-event reporting has been reduced, leaving a data gap. The Biden administration says the drug is safe, while the Trump-era review remains pending.
Verbatim Quotes
- “Every abortion facilitated by FDA’s action cancels Louisiana’s ban on medical abortions and undermines its policy that ‘every unborn child is human being from the moment of conception and is, therefore, a legal person,’” — 5th U.S. Circuit Court of Appeals
- “This is going to affect patients' access to abortion and miscarriage care in every state in the nation,” — Julia Kaye, ACLU lawyer
- “When telemedicine is restricted, rural communities, people with low incomes, people with disabilities, survivors of intimate partner violence and communities of color suffer the most.” — Julia Kaye, ACLU lawyer
- “Louisiana built this case on debunked, junk science,” — Mini Timmaraju, Reproductive Freedom for All President & CEO
Next Legal Steps
Louisiana and the FDA plan to seek a Supreme Court stay. The FDA’s safety review, due October 2026, will likely shape any future regulatory action.
